Los Angeles Times (LA Times) journalist Michael Hiltzik is the latest hired gun in the mainstream media to line up and take a pop-shot at the drug, Ivermectin.
In a breath of fresh air, a mainstream media opinion piece asks why the U.S. Food and Drug Administration (FDA) is denigrating a perfectly safe and effective drug?
A team of scientists at the University of Texas at Dallas developed a wearable sensor that can monitor the human body’s immune response to COVID-19 and other infections via the detection of molecules in human sweat.
On May 28, TrialSite reported on information regarding mRNA vaccine safety revealed by a freedom of information act (FOIA) request filed by a group of Canadian physicians who were concerned about COVID-19 mRNA vaccine safety.
Germany’s auto makers have announced vehicle sales are up in 2021, despite the COVID-19 pandemic and a sluggish economy. The most growth has come from electric vehicles (EVs), for which demand has skyrocketed.
Andrew Bannister’s article ‘Don’t mention Ivermectin; it’ll upset the vaccine rollout’ was published on BizNews.com in May. The article gained an extensive amount of traction, which isn’t all that surprising considering mainstream media’s lack of coverage on alternative Covid-19 treatment.
With the degree of passionate debate surrounding the use of ivermectin for the treatment and prevention of Covid-19, it is hard to believe that a mere seven months ago, the term ‘ivermectin’ was entirely foreign to most people.
TrialSite recently showcased what appears to be mounting safety issues with Sinopharm’s COVID-19 vaccine. Half-owned by the Chinese government, it’s one of a few controversial vaccines from China. Now doctors in the Southeastern Asian nation of Indonesia are dying after being vaccinated with CoronaVac, another COVID-19 vaccine developed by China’s Sinovac.
The recent upheaval in KwaZulu-Natal and Gauteng underscores an unmistakable truth: far from uplifting black South Africans and putting them on a par with their wealthier white compatriots who benefited from apartheid, over two decades of social engineering under the guise of Black Economic Empowerment (BEE) and related racial policies have produced dismal outcomes.
A reader recently asked me the following questions about the research I’ve conducted during the COVID-19 pandemic: “Have any of your fellow researchers disagreed with your findings?
After the ruin, disgrace, and misery of the recent anarchy, South Africans are witnessing something inspiring as shopping malls are rebuilt, shelves restocked, security enhanced, and business struggles back to normal.
President Cyril Ramaphosa has announced that several of South Africa’s lockdown regulations will be relaxed as the country moves to an adjusted level 3 lockdown with immediate effect.
A surge in Delta-variant driven COVID-19 cases concentrates in just a handful of states as there is, overall, an uptick in total cases across the United States.
An Israeli biotech has developed an investigational, proprietary protein oral delivery (POD™) technology in the development of oral vaccines that are now only available via an imposing injection.
Jamaica’s Minister of Health and Wellness recently signed the import permit to allow stocks of Ivermectin into Jamaica.
Drug control authorities around the world chose to dismiss or stay indifferent to the sustained efficacy of Ivermectin despite studies showing its effectiveness.
Recently, Laura Ingraham had Yale University epidemiologist Dr. Harvey Risch, a contributor to TrialSite News, as well as researcher and author Alex Berenson on her show to discuss taking an honest look at the trends behind breakthrough COVID-19 cases, or fully-vaccinated individuals who become infected with COVID-19, and also the growing call for more lockdowns and the use of masks.
The Biovac Institute reached a deal with Pfizer to prepare and deliver vaccine doses for the continent. It comes amid an increase of cases in Africa, where just 2% of the population have received a first dose.
In its latest weekly surveillance summary, the European Centre for Disease Prevention and Control (ECDC) documented that case rates in the European Union and the European Economic Area were at 89.6 per 100,000 people in the week ending July 11.
University of Iowa Carver College of Medicine led a multi-site study finding that the only formally approved drug by the U.S. Food and Drug Administration (FDA) actually led to lengthier hospitalization duration, or was associated with such an observation.
